Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with
biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled
proof-of-principle study
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)